EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

Beynon Abrahams iD, Anthonie Gerber, Donavon Charles Hiss iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25053066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Beynon Abrahams und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, Faculty of Health Sciences, University of the Free State, Bloemfontein 9301, South Africa. Hauptthemen laut MEDLINE: Doxorubicin, ErbB Receptors, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, National Research Foundation of South Africa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of the epidermal growth factor receptor (EGFR) in tumor progression and survival is often underplayed. Its expression and/or dysregulation is associated with disease advancement and poor patient outcome as well as drug resistance in breast cancer. EGFR is often overexpressed in breast cancer and particularly triple-negative breast cancer (TNBC), which currently lacks molecular targets. We examined the synergistic potential of an EGFR inhibitor (EGFRi) in combination with doxorubicin (Dox) in estrogen-positive (ER+) MCF-7 and MDA-MB-231 TNBC cell lines. The exposure of MDA-MB-231 and MCF-7 to EGFRi produced an IC50s of 6.03 µM and 3.96 µM, respectively. Dox induced MDA-MB-231 (IC50 9.67 µM) and MCF-7 (IC50 1.4 µM) cytotoxicity. Combinations of EGFRi-Dox significantly reduced the IC50 in MCF-7 (0.46 µM) and MBA-MB 231 (0.01 µM). Synergistic drug interactions in both cell lines were confirmed using the Bliss independence model. Pro-apoptotic Caspase-3/7 activation occurred in MCF-7 at 0.1–10 µM of EGFRi and Dox single treatments, whilst 1 μM Dox yielded a more potent effect on MDA-MB-231. EGFRi and Dox individually and in combination downregulated the EGFR gene expression in MCF-7 and MDA-MB-231 (p < 0.001). This study demonstrates EGFRi’s potential for eliciting synergistic interactions with Dox, causing enhanced growth inhibition, apoptosis induction, and downregulation of EGFR in both cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinErbB ReceptorsTriple Negative Breast NeoplasmsFemaleHumansApoptosisCell Line, TumorCell ProliferationMCF-7 CellsDrug Synergism

Stichwörter der Autor:innen

Bliss independencebreast cancerdoxorubicin (Dox)drug combinationepidermal growth factor receptor (EGFR) inhibitor (EGFRi)growth inhibitionsynergistic interactionstriple-negative breast cancer (TNBC)

Substanzen

DoxorubicinEGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, Faculty of Health Sciences, University of the Free State, Bloemfontein 9301, South Africa.
  • Department of Medical Biosciences, Faculty of Natural Sciences, University of the Western Cape, Bellville 7535, South Africa.

ORCID-Profile: Beynon Abrahams, Donavon Charles Hiss

Förderung

  • National Research Foundation
  • National Research Foundation of South Africa

Zitieren

APA

Abrahams, B., Gerber, A., & Hiss, D. C. (2024). Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25053066

Vancouver

Abrahams B, Gerber A, Hiss DC. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25053066

BibTeX
@article{Abrahams2024,
  author = {Abrahams, Beynon and Gerber, Anthonie and Hiss, Donavon Charles},
  title = {Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25053066}
}
Kostenlos starten →